Business Wire

Aqara Adds Presence Sensor FP2 to its Smart Sensor Portfolio

20.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Aqara, a leading provider of smart home products, expands its wide-ranged smart sensor portfolio with the introduction of the Presence Sensor FP2, a revolutionary sensor for precise human presence detection. Equipped with the millimeter wave (mmWave) radar technology, the FP2 solves many pain points of the traditional passive infrared (PIR) presence sensors and enables a more tailored and rich smart home experience. The new sensor is now available on the Company’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as selective Aqara retailers worldwide1.

Accurate human presence detection provides essential information for tailored smart home automations such as home security monitoring and energy management systems (e.g., automated lights, HVAC, home appliances control). The mmWave-based FP2 Presence Sensor takes a leap forward from the PIR motion sensors as the former detects a person’s presence with even the slightest movement such as the act of breathing. Gone are the frustrating experiences of having your smart lights turn off unintentionally because you were sitting still reading a book or working at the desk.

Moreover, the FP2 sensor raises the precision of human detection to the next level with its capability to monitor multiple zones and multiple targets simultaneously. The FP2 allows the user to define up to 30 zones within a room (up to 40 sq m/430 sq ft). For example, the living room and dining area can be configured as separate zones with individualized automations. This sensor tracks up to 5 persons at the same time2, making it possible to control different zones based on the real-time location of each family member. For instance, to dim the dining area lights and switch the TV on when the kids leave the dining table and move to the sofa, meanwhile to keep the kitchen light on when someone is washing the dishes.

The powerful capabilities of the FP2 sensor can also be used within the third-party smart home platforms including Apple Home, Amazon Alexa, Google Home, Home Assistant3 and more. Once the zones are set up in the Aqara Home app, the zone configuration can be synced to these platforms as multiple motion/occupancy sensors, allowing users to trigger zone-based automation with a wide variety of third-party smart home devices. Support of the new smart home standard, Matter, is also planned for the FP2, and will be added to the device via a subsequent OTA update4.

Aside from its precise presence detection and multi-zone automations, FP2 also has fall detection built-in5, which is particularly essential for senior citizens who are more vulnerable to fall injuries. Families and caregivers can be alerted by both local siren and remote alerts if the FP2 sensor detects a fall, which allows them to seek immediate assistance if necessary. The FP2 sensor can detect a fall at the home in a convenient way without the need to wear additional devices on the body. At the same time, unlike a typical security camera, the Sensor provides meaningful alerts and data without intruding on a person’s personal privacy.

Thanks to its powerful hardware, the FP2 sensor will be able to support much more cutting-edge features in the future such as posture detection, which not only recognizes falls but also other postures including standing, sitting, and lying. Sleep monitoring and respiratory rate detection capabilities could also be achieved via the FP2 in the future. These advanced features will be added to the FP2 sensor via future OTA updates4.

For more details of the Presence Sensor FP2, please visit our website.

  1. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real-time availability.
  2. The best result can be achieved in the case of tracking not more than 3 persons.
  3. The FP2 sensor can be added to Home Assistant using HomeKit Controller integration.
  4. Some features of the FP2 sensor such as Matter support, posture detection and sleep monitor are not available by the time of launch.
  5. The Presence Sensor FP2 is not a medical device, and can only be used for notification purposes. Ceiling-mounted installation is required for fall detection, and the monitoring area will decrease when the FP2 is ceiling-mounted. In fall detection mode, many functionalities of the FP2 become unavailable, including zone positioning and multi-person detection.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Inquiry:
media@aqara.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye